References of "Ortolani, S"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailRelationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Bruyère, Olivier ULg; Collette, Julien ULg; Rizzoli, R. et al

in Osteoporosis International (2010), 21

From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were ... [more ▼]

From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level. [less ▲]

Detailed reference viewed: 41 (19 ULg)
Full Text
Peer Reviewed
See detailEffects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier, Pierre; Roux, C.; Ortolani, S. et al

in Osteoporosis International (2009), 20

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33 ... [more ▼]

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women. [less ▲]

Detailed reference viewed: 48 (11 ULg)
Full Text
Peer Reviewed
See detailRelationship between Change in Femoral Neck Bone Mineral Density and Hip Fracture Incidence During Treatment with Strontium Ranelate
Bruyère, Olivier ULg; Roux, Christian; Badurski, J. et al

in Current Medical Research & Opinion (2007), 23(12), 3041-5

OBJECTIVE: Strontium ranelate (SR) increases bone mineral density (BMD) in postmenopausal osteoporotic women and reduces vertebral and non-vertebral fracture incidence. Hip fracture reduction has also ... [more ▼]

OBJECTIVE: Strontium ranelate (SR) increases bone mineral density (BMD) in postmenopausal osteoporotic women and reduces vertebral and non-vertebral fracture incidence. Hip fracture reduction has also been observed during 3-year treatment with SR in osteoporotic women at high risk of hip fracture. The objective of this study is to analyse the association between BMD changes and hip fracture incidence during treatment with SR. MATERIAL AND METHODS: In this post-hoc analysis, 465 women aged over 74 years with low BMD at the femoral neck (T-score < or = -2.4 according to NHANES normative values) were selected from the population of a recently published study (the Treatment of Peripheral Osteoporosis Study - TROPOS). BMD was assessed at the femoral neck at baseline and after a follow-up of 3 years. Hip fractures were reported by study investigators. RESULTS: After adjusting for age, body mass index, femoral neck BMD at baseline and number of prevalent vertebral fractures, we found that for each 1% increase in femoral neck BMD observed after 3 years, the risk to experience a hip fracture after 3 years decreased by 7% (95% CI: 1-14%) (p = 0.04). In patients experiencing a hip fracture over 3 years of treatment with SR, femoral neck BMD increased by (mean [SE]) 3.41 (1.02)% compared to 7.23 (0.81)% in patients without hip fracture (p = 0.02). CONCLUSION: In this post-hoc analysis of women undergoing 3 years of SR treatment, an increase in femoral neck BMD is associated with a decrease in hip fracture incidence. [less ▲]

Detailed reference viewed: 44 (9 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over five years in post menopausal osteoporotic women
Reginster, Jean-Yves ULg; Meunier, Pierre; Roux, Christian et al

in Arthritis and Rheumatism (2006, November), 54(Suppl),

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic women
Reginster, Jean-Yves ULg; Meunier, P. J.; Roux, Christian et al

in Osteoporosis International (2006, June), 17(Suppl.2), 14

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic women
Reginster, Jean-Yves ULg; Meunier, P. J.; Roux, Christian et al

in Osteoporosis International (2006, March), 17(Suppl.1), 11

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailstrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture
Reginster, Jean-Yves ULg; Rizzoli, René; Balogh, A. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 53

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailPatients at high risk of hip fracture benefit from treatment with strontium ranelate
Rizzoli, René; Reginster, Jean-Yves ULg; Diaz-Curiel, M. et al

in Osteoporosis International (2004, May), 15(Suppl.1), 18

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailPatients at high risk of hip fracture benefit from treatment with strontium ranelate
Rizzoli, R.; Reginster, Jean-Yves ULg; Diaz-Curiel, M. et al

in Calcified Tissue International (2004), 74(S1), 83-84

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture
Reginster, Jean-Yves ULg; Rizzoli, R.; Balogh, A. et al

in Calcified Tissue International (2004), 74(S1), 83

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture
Reginster, Jean-Yves ULg; Balogh, A.; Badurski, J. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 7-8

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailOptimizing patient adherence and persistence in strontium ranelate phase 3 program using a short term run-in study
Reginster, Jean-Yves ULg; Spector, Tim; Badurski, J. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 35-36

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailSupplementation of calcium-vitamin D should be adapted according to the patients status in international phase 3 program on osteoporosis
Reginster, Jean-Yves ULg; Diez-Perez, A.; Ortolani, S. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 35

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailA short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium-ranelate phase 3 program
Reginster, Jean-Yves ULg; Spector, T.; Badurski, J. et al

in Osteoporosis International (2002), 13(S1), 30

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailCalcium-vitamin D supplementation in clinical trials of osteoporosis should be titrated on the basis of pre-study assessments
Reginster, Jean-Yves ULg; Diez-Perez, A.; Ortolani, S. et al

in Osteoporosis International (2002), 13(S1), 24

Detailed reference viewed: 12 (3 ULg)